UA129588C2 - Спосіб лікування раку на моделі, яка має мутації esr1 - Google Patents

Спосіб лікування раку на моделі, яка має мутації esr1 Download PDF

Info

Publication number
UA129588C2
UA129588C2 UAA202103001A UAA202103001A UA129588C2 UA 129588 C2 UA129588 C2 UA 129588C2 UA A202103001 A UAA202103001 A UA A202103001A UA A202103001 A UAA202103001 A UA A202103001A UA 129588 C2 UA129588 C2 UA 129588C2
Authority
UA
Ukraine
Prior art keywords
elacestrant
fulvestrant
dose
subject
shi
Prior art date
Application number
UAA202103001A
Other languages
English (en)
Ukrainian (uk)
Inventor
Нітіша Пател
Нитиша Пател
Теєру Біхані
Тееру Бихани
Хейке Арлт
Ніанцзюн Тао
Нианцзюн Тао
Original Assignee
Радіус Фармасеутікалс, Інк.
Радиус Фармасеутикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Радіус Фармасеутікалс, Інк., Радиус Фармасеутикалс, Инк. filed Critical Радіус Фармасеутікалс, Інк.
Publication of UA129588C2 publication Critical patent/UA129588C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA202103001A 2018-12-06 2019-12-06 Спосіб лікування раку на моделі, яка має мутації esr1 UA129588C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (1)

Publication Number Publication Date
UA129588C2 true UA129588C2 (uk) 2025-06-11

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202103001A UA129588C2 (uk) 2018-12-06 2019-12-06 Спосіб лікування раку на моделі, яка має мутації esr1

Country Status (17)

Country Link
US (2) US20220016052A1 (https=)
EP (1) EP3890835A1 (https=)
JP (2) JP7497353B2 (https=)
KR (1) KR20210100135A (https=)
AU (1) AU2019392908B2 (https=)
BR (1) BR112021010141A2 (https=)
CA (1) CA3121918A1 (https=)
EA (1) EA202191256A1 (https=)
IL (1) IL283655A (https=)
JO (1) JOP20210138B1 (https=)
MA (1) MA54393A (https=)
MX (1) MX2021006412A (https=)
MY (1) MY208702A (https=)
PH (1) PH12021551327A1 (https=)
SG (1) SG11202105915UA (https=)
UA (1) UA129588C2 (https=)
WO (1) WO2020118202A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3055185T3 (en) * 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법

Also Published As

Publication number Publication date
US20250241875A1 (en) 2025-07-31
EP3890835A1 (en) 2021-10-13
JOP20210138A1 (ar) 2023-01-30
JP2024101017A (ja) 2024-07-26
WO2020118202A1 (en) 2020-06-11
PH12021551327A1 (en) 2022-04-25
JP2022511497A (ja) 2022-01-31
IL283655A (en) 2021-07-29
MY208702A (en) 2025-05-25
JP7497353B2 (ja) 2024-06-10
MX2021006412A (es) 2021-07-21
CA3121918A1 (en) 2020-06-11
EA202191256A1 (ru) 2021-10-06
JOP20210138B1 (ar) 2025-10-01
KR20210100135A (ko) 2021-08-13
MA54393A (fr) 2021-10-13
AU2019392908A1 (en) 2021-06-10
AU2019392908B2 (en) 2025-02-20
US20220016052A1 (en) 2022-01-20
SG11202105915UA (en) 2021-07-29
BR112021010141A2 (pt) 2021-08-24

Similar Documents

Publication Publication Date Title
US12582617B2 (en) Methods for treating cancer
US20260014153A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
US20250319044A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
AU2019324155A1 (en) Platelet count-agnostic methods of treating myelofibrosis
UA129588C2 (uk) Спосіб лікування раку на моделі, яка має мутації esr1
RU2822195C2 (ru) Способы лечения рака на моделях, имеющих мутации esr1
RU2820478C2 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
EA046925B1 (ru) Способы лечения рака на моделях, имеющих мутации esr1
RU2841076C2 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA047283B1 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака